Pharmaceutical firms get cold feet about potential OTC switches when they consider the costs for studies to update safety data for an ingredient, suggests Laura Mahecha, a health care market consultant for research firm Kline & Co.
During a June 27 webinar, “Key Issues Trending in the US OTC Market,” Mahecha noted that with safety "paramount for switch approval," data from a drug ingredient's initial approval for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?